Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Recruiting Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Events
    • Email Alerts
  • Company Information
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Information
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Events
  • Email Alerts

Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update

Aug 12, 2022

Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August

Aug 8, 2022

Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance

Aug 3, 2022

Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July

Jul 7, 2022

Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication

Jun 29, 2022

Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting

Jun 8, 2022

Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

May 19, 2022

Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update

May 13, 2022

Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference

May 11, 2022

Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

Apr 28, 2022
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...38
Ocuphire Pharma, Inc.
© Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use